Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ablynx has extended its global strategic nanobody alliance with Boehringer Ingelheim for two-years, which will run until September 2014.
Subscribe to our email newsletter
The extension will allow the existing ten Nanobody programs to advance to a stage where Boehringer can progress each program into development.
Ablynx will receive a total of €6.6m in additional research funding from Boehringer, some of which will be in advance, the companies said.
As per the agreement signed in 2007, Ablynx has already received over €58m from Boehringer.
Ablynx CEO and chairman Edwin Moses said as a result of the successful collaboration, there are now two Nanobody programs already in pre-clinical development and seven Nanobodies at various stages in discovery across multiple disease areas.
"We are very pleased to have eleven Nanobody programmes potentially able to make an important contribution to Boehringer Ingelheim’s R&D pipeline," Moses added.